<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development — Live Feed</title><link>https://www.live-feeds.com/feed/pfizer-signs-1-5-billion-deal-with-blackstone-to-fund-weight-loss-drug-development</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/pfizer-signs-1-5-billion-deal-with-blackstone-to-fund-weight-loss-drug-development/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>Pfizer and Blackstone agree up to $1.5 billion co-funding deal for obesity drug berobenatide</title><link>https://www.live-feeds.com/feed/pfizer-signs-1-5-billion-deal-with-blackstone-to-fund-weight-loss-drug-development</link><guid isPermaLink="false">https://www.live-feeds.com/feed/pfizer-signs-1-5-billion-deal-with-blackstone-to-fund-weight-loss-drug-development#u203361</guid><pubDate>Mon, 16 Nov 2026 03:36:38 +0000</pubDate><description>Pfizer has signed a strategic funding agreement with Blackstone Life Sciences to advance its monthly GLP-1 obesity drug berobenatide through Phase 3 studies. Blackstone will provide up to $1.5 billion through 2028, according to PharmaExec. Pfizer acquired the asset by winning a bidding war for Metsera, the drug&amp;#039;s previous owner. The deal supports a sprawling Phase 3 program as Pfizer seeks to compete in the crowded weight-loss drug market.Why it mattersThe agreement shifts much of the financial risk of late-stage obesity drug development onto Blackstone while Pfizer retains a path to comm</description></item>
</channel></rss>